Drug Profile
Lonafarnib - Eiger Biopharmaceuticals
Alternative Names: EBP 994; MK-6336; Sarasar; SCH-066336; SCH-66336; ZokinvyLatest Information Update: 22 Jan 2024
Price :
$50
*
At a glance
- Originator Schering-Plough
- Developer AnGes; Eiger BioPharmaceuticals, Inc.; Merck & Co; Schering-Plough
- Class Amides; Antineoplastics; Antivirals; Benzene derivatives; Halogenated hydrocarbons; Piperidines; Pyridines; Small molecules
- Mechanism of Action Farnesyltranstransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Progeria
- Phase III Hepatitis D
- Discontinued Breast cancer; Cancer; Chronic myelomonocytic leukaemia; Glioblastoma; Glioma; Leukaemia; Myelodysplastic syndromes; Non-small cell lung cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
Most Recent Events
- 18 Jan 2024 Registered for Progeria in Japan (PO)
- 31 Dec 2023 Eiger BioPharmaceuticals applies for named patient program approvals in Spain and United kingdom
- 10 Nov 2023 Updated efficacy data from the phase III D-LIVR trial in Hepatitis D presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)